Prelude Therapeutics Incorporated (PRLD)
NASDAQ: PRLD · Real-Time Price · USD
0.7897
-0.0319 (-3.88%)
May 6, 2025, 4:00 PM EDT - Market closed

Company Description

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients.

It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors.

The company’s CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB.

Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Prelude Therapeutics Incorporated
Prelude Therapeutics logo
Country United States
Founded 2016
IPO Date Sep 25, 2020
Industry Biotechnology
Sector Healthcare
Employees 131
CEO Krishna Vaddi

Contact Details

Address:
175 Innovation Boulevard
Wilmington, Delaware 19805
United States
Phone 302 467 1280
Website preludetx.com

Stock Details

Ticker Symbol PRLD
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $19.00
CIK Code 0001678660
CUSIP Number 74065P101
ISIN Number US74065P1012
Employer ID 81-1384762
SIC Code 2834

Key Executives

Name Position
Dr. Krishna Vaddi D.V.M., Ph.D. Founder, Chief Executive Officer and Director
Dr. Edna Huang M.D. President and Chief Medical Officer
Bryant David Lim J.D. Chief Financial Officer, Chief Legal Officer and Corporate Secretary
Aimee Crombie Ph.D. Senior Vice President and Head of Strategic Planning and Operations
Dr. Madhu Pudipeddi Ph.D. Senior Vice President of Technical Operations
Dr. Peggy A. Scherle Ph.D. Chief Scientific Officer
Michele Porreca M.B.A. Chief People Officer
Dr. Andrew P. Combs Ph.D. Executive Vice President and Chief Chemistry Officer
Naveen Babbar Ph.D. Senior Vice President of Translation Medicine
Dr. William B. Novotny M.D. Senior Vice President of Clinical Development

Latest SEC Filings

Date Type Title
May 6, 2025 10-Q Quarterly Report
May 6, 2025 8-K Current Report
Apr 29, 2025 ARS Filing
Apr 29, 2025 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Apr 29, 2025 DEF 14A Other definitive proxy statements
Apr 25, 2025 8-K Current Report
Apr 11, 2025 PRE 14A Other preliminary proxy statements
Mar 28, 2025 8-K Current Report
Mar 10, 2025 S-8 Securities to be offered to employees in employee benefit plans
Mar 10, 2025 10-K Annual Report